Scotia Wealth Management
Latest Top Picks
Preferred H shares? The preferreds are yielding about 9%. This was issued at $25 originally with a yield just over 4%. Buying at $11.50 affords the high yield. It will reset in 2023, around 2.5% based on current interest rates (versus the 4% it was originally issued at). If interest rates go up in 2023 the yield will increase, but do investors think rates will be that much higher?
Preferred H shares? The preferreds are yielding about 9%. This was issued at $25 originally with a yield just over 4%. Buying at $11.50 affords the high yield. It will reset in 2023, around 2.5% based on current interest rates (versus the 4% it was originally issued at). If interest rates go up in 2023 the yield will increase, but do investors think rates will be that much higher?
JNJ vs ABBV? He likes JNJ as a long term winner. It may be too expensive. ABBV was a risky company until they purchased Allergan and diversified their business more. ABBV trades at 8.4 times PE and earnings are expected to grow by 8% and have nice, safe dividend. They are still tethered to Humara, which has a lot of generics being developed. He would favor ABBV, although it is a little riskier than JNJ.
JNJ vs ABBV? He likes JNJ as a long term winner. It may be too expensive. ABBV was a risky company until they purchased Allergan and diversified their business more. ABBV trades at 8.4 times PE and earnings are expected to grow by 8% and have nice, safe dividend. They are still tethered to Humara, which has a lot of generics being developed. He would favor ABBV, although it is a little riskier than JNJ.
JNJ vs ABBV? He likes JNJ as a long term winner. It may be too expensive. ABBV was a risky company until they purchased Allergan and diversified their business more. ABBV trades at 8.4 times PE and earnings are expected to grow by 8% and have nice, safe dividend. They are still tethered to Humara, which has a lot of generics being developed. He would favor ABBV, although it is a little riskier than JNJ.
JNJ vs ABBV? He likes JNJ as a long term winner. It may be too expensive. ABBV was a risky company until they purchased Allergan and diversified their business more. ABBV trades at 8.4 times PE and earnings are expected to grow by 8% and have nice, safe dividend. They are still tethered to Humara, which has a lot of generics being developed. He would favor ABBV, although it is a little riskier than JNJ.
The company has good businesses. Their problem was the balance sheet. They will be 3 times debt-to-EBITDA. They have more funds for M&A, which could help them make some interesting acquisitions. He likes the distribution and the management team. They just partnered with Brookfield, which gives a strong vote of confidence. Its valuation is reasonable. Not the first place he would put capital, but you would do well if you already own it.
The company has good businesses. Their problem was the balance sheet. They will be 3 times debt-to-EBITDA. They have more funds for M&A, which could help them make some interesting acquisitions. He likes the distribution and the management team. They just partnered with Brookfield, which gives a strong vote of confidence. Its valuation is reasonable. Not the first place he would put capital, but you would do well if you already own it.
SU vs CPG? During the recovery of energy prices, SU has seen its balance sheet improve dramatically. CPG has worked hard and have improved their debt levels. At current oil price levels, both look okay. If he was putting money into energy, he would prefer going with the heavy weight -- SU.
